Al-Hakeem Dalal Abdullah, Fedele Stefano, Carlos Roman, Porter Stephen
Oral Medicine Unit, Division of Maxillofacial Diagnostic, Medical and Surgical Sciences, UCL Eastman Dental Institute for Oral Health Care Sciences, 256 Gray's Inn Road, London WC1X 8LD, UK.
Oral Oncol. 2007 Jan;43(1):4-14. doi: 10.1016/j.oraloncology.2006.03.011. Epub 2006 Oct 24.
Extranodal NK/T-cell lymphoma, nasal type (ENKTCL), previously known as lethal midline granuloma is a distinct clinico-pathological entity associated with Epstein-Barr virus that typically causes destruction of the midface, palatal and orbital walls. In addition, ENKTCL can involve the skin, soft tissue, testes, gastrointestinal and upper respiratory tract. ENKTCL neoplastic cells express some T-cell associated antigens, most commonly CD2 and cytoplasmic CD3epsilon and, in favour of an NK-cell origin, CD56. Early stage disease may respond to radiotherapy alone, however late stage disease does not respond well to any available therapies. Overall, patients with ENKTCL have a cumulative probability of survival at 5 years ranging from 37.9% to 45.3%.
结外NK/T细胞淋巴瘤,鼻型(ENKTCL),以前称为致死性中线肉芽肿,是一种与EB病毒相关的独特临床病理实体,通常会导致中面部、腭和眶壁破坏。此外,ENKTCL可累及皮肤、软组织、睾丸、胃肠道和上呼吸道。ENKTCL肿瘤细胞表达一些T细胞相关抗原,最常见的是CD2和细胞质CD3ε,支持NK细胞起源的是CD56。早期疾病可能仅对放疗有反应,然而晚期疾病对任何现有治疗反应不佳。总体而言,ENKTCL患者5年累积生存率在37.9%至45.3%之间。